netFormulary NHS
Milton Keynes Formulary
Milton Keynes University Hospital NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes Clinical Commissioning Group
Milton Keynes Community Health Services
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

 

NHS Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation B04/P/a

Contacting Milton Keynes Hospital

      
For Haematology and Oncology:

  • During hours: Macmillan Unit on 01908 243671; Internal Ext 5111 or 5112
  • Out of hours: Advanced Nurse Practitioner on bleep 1090    

Paediatric patients:

  • During hours: Paediatric Day Community Unit on 01908 242703; Internal Ext 2703      

Pharmacy:

  • Cancer and Aseptic Services Manager on bleep 1721
  • Aseptic Unit 01908 243952
  • On-call pharmacist via switchboard 01908 660033
Chapter Links...
 Details...
08.02.03  Expand sub section  Anti-lymphocyte monoclonal antibodies
Alemtuzumab (Lemtrada®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

Lemtrada® Concentrate for IV infusion 10mg/mL

 

 
Link  NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis
   
AvelumabBlack Triangle (Bavencio®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Bavencio® 200mg/10mL concentrate for solution for infusion vials

NB - mixture of routine Commissioning and Cancer Drugs Fund

 
Link  NICE TA517: Avelumab for treating metastaic Merkel cell carcinoma
Link  NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma
Link  NICE TA691: Avelumab for untreated metastatic Merkel cell carcinoma
   
Gemtuzumab ozogamicin (Mylotarg)
View adult BNF View SPC online View childrens BNF
Formulary
Red

5mg powder for concentrate for solution for infusion vials

 

 
Link  NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
   
Obinutuzumab (Gazyvaro®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Gazyvaro® Concentrate for intravenous infusion, 25mg/mL (40mL vial)

Notes:

Use in line with NICE guidance and NHSE Position Statement (see links below).

 
Link  NICE TA343: Obinutuzumab with chlorambucil for CLL
Link  NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Link  NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma
Link  NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab
   
Ocrelizumab (Ocrevus®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Ocrevus® Solution for infusion 30mg per ml

 

 
Link  NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis
Link  NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis
   
Ofatumumab (Arzerra®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Arzerra® Concentrate for intravenous infusion, 100mg in 5ml, 1000mg in 50ml vials

 

 
Link  MHRA: Ofatumumab: screen for hepatitis B virus before treatment
Link  MHRA: Risk of serious and fatal infusion reactions—always give premedication and monitor carefully
Link  NICE TA344: Ofatumumab with chlorambucil or bendamustine for CLL
   
Polatuzumab VedotinBlack Triangle (Polivy®)
Formulary
Red
High Cost Medicine
NHS England

140 mg vial, powder for solution for infusion

 

 

 
Link  NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
   
Rituximab (MabThera®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

MabThera® Concentrate for IV infusion 100mg in 10mL, 500mg in 50mL

 

 

 
Link  NICE TA137: Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma
Link  NICE TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia
Link  NICE TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia
Link  NICE TA226: Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma
Link  NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma
Link  NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
   
Rituximab (MabThera®)
(Subcutaneous injection)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
   
Rituximab (Truxima®)
(Biosimilar)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  NHS England: For the eradication of inhibitors in acquired haemophilia
Link  NHS England: Graft versus host disease
Link  NHS England: Neuromyelitis optica
Link  NICE guidelines for rituximab
Link  Rituximab for ITP-NICE evidence summary
   
 ....
 Non Formulary Items
Alemtuzumab  (MabCampath®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Green

Routine prescribing within licensed indication  

Amber 1

Specialist recommendation followed by GP initiation and continuation  

Amber 2

Specialist or GP initiation in line with local guideline after 1st line failure followed by GP continuation   

Amber 3

Specialist initiation and stabilisation followed by GP continuation  

Amber SCG

Specialist initiation and stabilisation followed by GP continuation in line with an agreed shared care guideline  

Red

Hospital or specialist prescribing only  

Red Red

These medicines have been evaluated and rejected by MKPAG and are NOT approved for use within MK. They are not recommended for use because of lack of clinical effectiveness, cost effectiveness or safety.  

netFormulary